LifeStance Health Group, Inc.

During our fiscal quarter ended December 31, 2025, one of our directors or officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)entered into, modified (as to amount, price or timing of trades) orterminated (i) contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information or (ii) non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K).

Robert Bessler, Director

On December 17, 2025, Robert Bessler, Director, entered into a Rule 10b5-1 trading plan pursuant to which Mr. Bessler, acting through a broker, may sell up to an aggregate of 1,500,000 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from March 24, 2026 to March 31, 2027. The plan is scheduled to terminate on March 31, 2027, subject to earlier termination upon the sale of all shares subject to the plan or the expiration of all sale orders under the plan, upon termination by Mr. Bessler or the broker, or as otherwise provided in the plan.